Trial Profile
A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and Ipilimumab
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Hyaluronidase/rituximab (Primary) ; Hyaluronidase/rituximab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 17 Jun 2021 Planned End Date changed from 31 Oct 2022 to 31 Oct 2024.
- 17 Jun 2021 Planned primary completion date changed from 31 Oct 2021 to 31 Oct 2023.
- 07 Jun 2019 Status changed from not yet recruiting to recruiting.